Podcast appearances and mentions of Evan J Lipson

  • 26PODCASTS
  • 65EPISODES
  • 40mAVG DURATION
  • 1MONTHLY NEW EPISODE
  • Aug 9, 2024LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about Evan J Lipson

Latest podcast episodes about Evan J Lipson

Research To Practice | Oncology Videos
Skin Cancer | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers

Research To Practice | Oncology Videos

Play Episode Listen Later Aug 9, 2024 59:36


Featuring perspectives from Dr Evan J Lipson, including the following topics: Introduction: Johns Hopkins University (0:00) Metastatic Melanoma (8:21) Nonmetastatic Melanoma and Other Skin Cancers (34:20) CME information and select publications

Dermatologic Oncology Update
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers

Dermatologic Oncology Update

Play Episode Listen Later Aug 9, 2024 59:35


Dr Evan J Lipson from the Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, summarizes major clinical advances over the past year for treating skin cancers.

Oncology Today with Dr Neil Love
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers

Oncology Today with Dr Neil Love

Play Episode Listen Later Aug 8, 2024 59:35


Dr Evan J Lipson from the Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland, summarizes major clinical advances over the past year for treating skin cancers, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/YiR2023/Skin).

CME in Minutes: Education in Dermatology
Evan J. Lipson, MD - Real Talk About Maximizing Care in Advanced Melanoma: Balancing Benefit and Risk Using Dual Immunotherapy Regimens

CME in Minutes: Education in Dermatology

Play Episode Listen Later Feb 14, 2024 13:24


Please visit answersincme.com/AUY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the role of dual immunotherapeutic approaches to the management of advanced melanoma. Upon completion of this activity, participants should be better able to: Review the clinical goals of patients with advanced melanoma receiving immunotherapy-based treatment; Describe the long-term clinical profiles of dual immunotherapeutic approaches to the management of advanced melanoma; and Outline evidence-based, immunotherapy-focused treatment plans for appropriate patients with advanced melanoma to optimize long-term patient outcomes.

Research To Practice | Oncology Videos
Melanoma and Nonmelanoma Skin Cancers | Evan J Lipson, MD

Research To Practice | Oncology Videos

Play Episode Listen Later Aug 17, 2023 49:25


Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers | Faculty Presentation 2: Localized Melanoma and Other Types of Skin Cancer — Evan J Lipson, MD CME information and select publications

Research To Practice | Oncology Videos
Melanoma and Nonmelanoma Skin Cancers | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers

Research To Practice | Oncology Videos

Play Episode Listen Later Aug 17, 2023 63:47


Featuring perspectives from Dr Omid Hamid and Dr Evan J Lipson, including the following topics: Introduction: Immunology of Melanoma (0:00) Melanoma (8:26) Cutaneous Squamous Cell Carcinoma (43:15) Basal Cell Carcinoma and Merkel Cell Carcinoma (52:55) CME information and select publications

Dermatologic Oncology Update
Year in Review — Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Oncology: Melanoma and Nonmelanoma Skin Cancers Edition

Dermatologic Oncology Update

Play Episode Listen Later Aug 17, 2023 63:46


Featuring a discussion on the most impactful updates from 2022 in the management of melanoma and nonmelanoma skin cancers with Dr Omid Hamid and Dr Evan J Lipson, moderated by Dr Neil Love.

Oncology Today with Dr Neil Love
Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Melanoma and Nonmelanoma Skin Cancers

Oncology Today with Dr Neil Love

Play Episode Listen Later Aug 16, 2023 63:38


Featuring perspectives from Dr Omid Hamid and Dr Evan J Lipson moderated by Dr Neil Love. Produced by Research to Practice. CME information and select publications here (http://www.researchtopractice.com/YiR2022/SkinCancers).

Research To Practice | Oncology Videos
BRAF-Mutant Melanoma | Meet The Professor: Management of BRAF-Mutant Melanoma — Part 2

Research To Practice | Oncology Videos

Play Episode Listen Later Jan 18, 2022 59:07


Featuring perspectives from Dr Jason Luke, including the following topics:  Introduction (0:00) DREAMseq Phase III Study (3:03) Case: A woman in her mid-50s with metastatic melanoma and a BRAF V600K mutation — Evan J Lipson, MD (18:08) Case: A man in his mid-60s with metastatic melanoma and a BRAF V600E mutation — Raji Shameem, MD (22:23) Case: A man in his late 60s with metastatic melanoma and a BRAF V600K mutation — Syed F Zafar, MD (33:04) Case: A man in his late 70s with melanoma and a history of transient ischemic attacks — Elizabeth Guancial, MD (37:39) Case: A man in his late 40s with resectable melanoma — Dr Lipson (42:38) Case: A man in his mid-50s with metastatic melanoma and a BRAF mutation — Allan Freedman, MD (46:08) Journal Club with Dr Luke (49:49) Beyond the Guidelines (52:39) CME information and select publications

PeerView Gastroenterology CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice

PeerView Gastroenterology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 18, 2021 27:11


Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 18, 2021 27:11


Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 18, 2021 27:06


Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 18, 2021 27:11


Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 18, 2021 27:06


Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 18, 2021 27:11


Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 18, 2021 27:06


Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 18, 2021 27:06


Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 18, 2021 27:11


Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 18, 2021 27:06


Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

Play Episode Listen Later Jun 18, 2021 27:11


Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.

PeerView Gastroenterology CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice

PeerView Gastroenterology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 18, 2021 27:06


Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jun 18, 2021 27:06


Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Evan J. Lipson, MD - Analyzing the Pros and Cons of Standard and Alternative Dosing Regimens of Immunotherapies and Combinations in Modern Oncology Practice

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Jun 18, 2021 27:11


Go online to PeerView.com/GAQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in immuno-oncology discusses modern management of patients with a range of cancers using immune checkpoint inhibitors, focusing on dosing and administration schedules based on the latest safety and efficacy considerations. Upon completion of this activity, participants will be able to: Describe the mechanisms of action, rationale, pharmacokinetic and pharmacodynamic profiles, and established and updated dosing recommendations for available immune checkpoint inhibitors and combination therapies for patients with cancer, Identify key safety and efficacy considerations among other pros and cons related to immunotherapy dosing and dose schedules, particularly with regard to extended-interval dosing, flipped dosing, dosing based on tumor type, and dose modification to minimize toxicity, Develop a plan to personalize immunotherapy selection, dosing, and administration for patients with cancer, taking into account pros and cons of relevant standard and alternative dosing approaches, current recommendations, appropriate immune-related adverse event monitoring strategies, and the clinical constraints that have been exacerbated by the COVID-19 pandemic.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Best Practices for Recognizing & Managing Immune-Related Adverse Events in the Emergency Department: Become Aware, Stay Alert, Change Your Practice, & Keep Patients With Cancer Safe

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Dec 27, 2019 81:17


Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Best Practices for Recognizing & Managing Immune-Related Adverse Events in the Emergency Department: Become Aware, Stay Alert, Change Your Practice, & Keep Patients With Cancer Safe

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Dec 27, 2019 81:17


Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Best Practices for Recognizing & Managing Immune-Related Adverse Events in the Emergency Department: Become Aware, Stay Alert, Change Your Practice, & Keep Patients With Cancer Safe

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Dec 27, 2019 81:32


Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology

PeerView Clinical Pharmacology CME/CNE/CPE Video
Evan J. Lipson, MD - Best Practices for Recognizing & Managing Immune-Related Adverse Events in the Emergency Department: Become Aware, Stay Alert, Change Your Practice, & Keep Patients With Cancer Safe

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Dec 27, 2019 81:32


Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Best Practices for Recognizing & Managing Immune-Related Adverse Events in the Emergency Department: Become Aware, Stay Alert, Change Your Practice, & Keep Patients With Cancer Safe

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Dec 27, 2019 81:32


Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Best Practices for Recognizing & Managing Immune-Related Adverse Events in the Emergency Department: Become Aware, Stay Alert, Change Your Practice, & Keep Patients With Cancer Safe

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

Play Episode Listen Later Dec 27, 2019 81:17


Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Best Practices for Recognizing & Managing Immune-Related Adverse Events in the Emergency Department: Become Aware, Stay Alert, Change Your Practice, & Keep Patients With Cancer Safe

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Dec 27, 2019 81:17


Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Best Practices for Recognizing & Managing Immune-Related Adverse Events in the Emergency Department: Become Aware, Stay Alert, Change Your Practice, & Keep Patients With Cancer Safe

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Dec 27, 2019 81:32


Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Best Practices for Recognizing & Managing Immune-Related Adverse Events in the Emergency Department: Become Aware, Stay Alert, Change Your Practice, & Keep Patients With Cancer Safe

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

Play Episode Listen Later Dec 27, 2019 81:32


Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Best Practices for Recognizing & Managing Immune-Related Adverse Events in the Emergency Department: Become Aware, Stay Alert, Change Your Practice, & Keep Patients With Cancer Safe

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Dec 27, 2019 81:17


Go online to PeerView.com/RQF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium at the American College of Emergency Physicians, an emergency medicine and an oncology experts discuss the range of unique toxicities of inflammatory nature known as immune-related adverse events (irAEs) that can occur as a result of immune activation caused by immune checkpoint inhibitors, as well as how to diagnose and manage these events in the emergency department in patients with cancer. Upon completion of this activity, participants will be able to: Summarize the current understanding of how to harness the human immune system in the treatment of cancer and the characteristics, mechanisms of action, and approvals/indications of the immune checkpoint inhibitor class of agents used in oncology, Describe the reasons for and mechanisms underlying the development of irAEs associated with cancer immunotherapies, Discuss the more and less common irAEs associated with immune checkpoint inhibitors and combinations, including those most likely to be encountered by EM professionals in the emergency department (ED), Outline the general and organ/site-specific recommendations for recognition, evaluation, diagnosis/differential diagnosis, and management of irAEs in the ED, Implement recommended strategies for triage, evaluation, diagnosis, and management of relevant irAEs in EM settings in collaboration with oncology

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 16, 2019 33:09


Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.

PeerView Clinical Pharmacology CME/CNE/CPE Video
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Aug 16, 2019 33:17


Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 16, 2019 33:09


Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Aug 16, 2019 33:17


Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Aug 16, 2019 33:17


Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Aug 16, 2019 33:09


Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 10, 2019 33:09


Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 10, 2019 33:09


Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 10, 2019 33:17


Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 10, 2019 33:09


Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 10, 2019 33:09


Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 10, 2019 33:17


Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 10, 2019 33:09


Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 10, 2019 33:17


Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.

PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 10, 2019 33:17


Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.

PeerView Gastroenterology CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

PeerView Gastroenterology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Jul 10, 2019 33:09


Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.

PeerView Gastroenterology CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

PeerView Gastroenterology CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 10, 2019 33:17


Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Beyond the Basics of Immuno-Oncology: Navigating Clinical Challenges to Maximize the Benefits and Minimize the Risks of Cancer Immunotherapies

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

Play Episode Listen Later Jul 10, 2019 33:17


Go online to PeerView.com/JHZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the use of immunotherapies for cancer discuss the expanding role of immunotherapy in oncology, focusing on current and emerging strategies, immune-mediated adverse reactions, and best practices for their identification and management, as well as the use of immunotherapy in more challenging patient populations. Upon completion of this activity, participants will be able to: Discuss the current and expanding role of cancer immunotherapies across the oncologic spectrum, Characterize the full range of potential immune-mediated adverse reactions (IMARs) associated with cancer immunotherapies and combinations, Implement best practices for optimal evaluation, diagnosis, and management of IMARs in patients undergoing treatment with cancer immunotherapies and combinations, including less commonly occurring adverse effects and rare manifestations of common toxicities, Establish strategies for assessment, monitoring, and management of challenging patient populations that may benefit from cancer immunotherapies.

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 11, 2019 32:42


Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Play Episode Listen Later Mar 11, 2019 32:50


Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED

PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

Play Episode Listen Later Mar 11, 2019 32:50


Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 11, 2019 32:42


Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED

PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 11, 2019 32:42


Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED

PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast

Play Episode Listen Later Mar 11, 2019 32:50


Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED

PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 11, 2019 32:42


Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists

PeerView Clinical Pharmacology CME/CNE/CPE Video
Evan J. Lipson, MD - Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED

PeerView Clinical Pharmacology CME/CNE/CPE Video

Play Episode Listen Later Mar 11, 2019 32:50


Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists

PeerView Internal Medicine CME/CNE/CPE Video Podcast
Evan J. Lipson, MD - Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Play Episode Listen Later Mar 11, 2019 32:50


Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists

PeerView Internal Medicine CME/CNE/CPE Audio Podcast
Evan J. Lipson, MD - Urgent Care of Patients Receiving Cancer Immunotherapy: Recognition and Management of Immune-Mediated Adverse Reactions in the ED

PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Play Episode Listen Later Mar 11, 2019 32:42


Go online to PeerView.com/CBT860 to view the entire program with slides. In this activity, experts in oncology and emergency medicine discuss principles of using immunotherapy to treat cancer, focusing specifically on the development of and recommendations for identifying, grading, and managing IMARs. Upon completion of this activity, participants will be able to: Describe the basic principles of harnessing the human immune system in the treatment of cancer, including the mechanistic aspects of immune checkpoint inhibition and development of immune-mediated adverse reactions (IMARs), Characterize the spectrum of IMARs: organ systems potentially impacted, presenting symptoms, and timing of occurrence, Discuss the general and organ-specific recommendations for evaluation, grading, and management of IMARs, including specific considerations for emergency care settings, Implement recommended strategies for triage and management of IMARs in the emergency care setting, Coordinate assessment and transition of care of patients experiencing IMARs with oncologists and medical subspecialists

GRACEcast
Managing Immunotherapy Side Effects

GRACEcast

Play Episode Listen Later Jan 14, 2016 12:39


Dr. Evan J. Lipson, Johns Hopkins University, discusses the incidence and treatment of side effects of immunotherapy and compares them to chemotherapy toxicities.

GRACEcast ALL Subjects audio and video
Managing Immunotherapy Side Effects

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jan 14, 2016 12:39


Dr. Evan J. Lipson, Johns Hopkins University, discusses the incidence and treatment of side effects of immunotherapy and compares them to chemotherapy toxicities.

GRACEcast Treatments and Support Video
Managing Immunotherapy Side Effects

GRACEcast Treatments and Support Video

Play Episode Listen Later Jan 14, 2016 12:39


Dr. Evan J. Lipson, Johns Hopkins University, discusses the incidence and treatment of side effects of immunotherapy and compares them to chemotherapy toxicities.

Cancer.Net Podcasts
Giving Patients a Way to Share Their Stories, with Evan Lipson, MD

Cancer.Net Podcasts

Play Episode Listen Later Apr 3, 2011 6:08


This podcast is led by ASCO member, Evan J. Lipson, MD. Dr. Lipson recently launched a website, called Seize the Days, that offers people with cancer and their families an opportunity to record and preserve audio interviews as a way to share their personal stories with others. In this podcast, Dr. Lipson discusses Seize the Days and provides stories from patients about how a cancer diagnosis affected their lives. ASCO would like to thank Dr. Lipson and his patients for sharing these stories. Quality of Life